Filing Details
- Accession Number:
- 0000950170-25-093035
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-07-02 16:30:04
- Reporting Period:
- 2025-06-30
- Filing Date:
- 2025-07-02
- Accepted Time:
- 2025-07-02 16:30:04
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1841387 | Candel Therapeutics Inc. | CADL | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1618364 | Garrett William Nichols | C/O Candel Therapeutics, Inc. 117 Kendrick St., Suite 450 Needham MA 02494 | Chief Medical Officer | No | No | No | No |
Transaction Summary
| Sold: | 781 shares | Avg. Price: $5.04 | Total Value: $3,936.24 |
| Number of Shares After Transactions: | 52,493 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-06-30 | 781 | $1.29 | 53,274 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-06-30 | 781 | $5.04 | 52,493 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-06-30 | 781 | $0.00 | 781 | $1.29 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 30,314 | 2033-04-28 | No | 4 | M | Direct |
Footnotes
- This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.
- This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date.
Billionaire Hedge Funds
